Rabeprazole

Research use only, not for human use.

Rabeprazole (LY307640) is an H+/K+-ATPase inhibitor that inhibits cell proliferation in gastric epithelial cells by targeting STAT3-mediated glycolysis and can be used in the study of gastric ulcers.

Rabeprazole (LY307640) is a second-generation proton pump inhibitor (PPI) that irreversibly inactivates gastric H+/K+-ATPase. Rabeprazole induces apoptosis. Rabeprazole acts as an uridine nucleoside ribohydrolase (UNH) inhibitor with an IC50 of 0.3 μM. Rabeprazole can be used for the research of gastric ulcerations and gastroesophageal reflux.

Rabeprazole attenuates the cell viability of the human gastric cancer cells following treatment with 0.2 mM for 16 hours.Rabeprazole completely inhibits the phosphorylation of ERK1/2 in the MKN-28 cells. The gastric cancer cell line MKN-28 is cultured in acidic culture media (pH 5.4) for 2 hours. Pretreatment with Rabeprazole (0.2 mM for 2 hours) leads to strong inhibition of ERK1/2 phosphorylation in the MKN-28 cells.Cell Viability Assay Cell Line:Three gastric cancer cell lines KATO III, MKN-28 and MKN-45 Concentration:0.2 mM Incubation Time:16 hours Result:Treatment resulted in the attenuation of viability in all cancer cell lines tested, the cell viability of the MKN-28 cells significantly decreased compared with the KATO III and MKN-45 cells, respectively. Cell Viability Assay Cell Line:Three gastric cancer cell lines (KATO III, MKN-28 and MKN-45) Concentration: 0.2 mM Incubation Time:Pretreatment for 2 hours Result:Led to strong inhibition of ERK 1/2 phosphorylation in the MKN-28 cells, but a similar effect was not observed in the KATO III and MKN-45 cells.

Rabeprazole (10 mg/kg; P.O.; every 48 h for 18 weeks) course leads to a significant decline in bone mineral density (BMD) and decreases serum calcium level and produces secondary hyperparathyroidism in female mice.Animal Model:Female Swiss albino mice (body weight equals 18-26 g) Dosage:10 mg/kg Administration:Oral administration; every 48 h for 18 weeks Result:Showed significantly lower serum calcium level compared to the vehicle treated group (5.5±2.07 vs. 9.68±2.77).

——

Cell Cycle/DNA Damage

Potassium Channel

Potassium Channel | STAT

——

——

117976-89-3

359.44

C18H21N3O3S

>98% (HPLC)

——

COCCCOc1ccnc(CS(=O)c2nc3ccccc3[nH]2)c1C

——

(-20℃)

With Ice Pack

≥ 2 years